HER2-positive (HER2+) breast cancer treatments come with a range of unpleasant side effects. However, there are strategies ...

Breast cancers can be classified into subgroups that hint at the aggressiveness of the cancer and the likelihood that the ...

A NEW breast cancer therapy shown to significantly reduce the risk of cancer recurrence and improve disease-free survival in women is now approved for use in Thailand.[1,2,3] ...

Breast cancers at all stages are defined by the structure of their genomes, researchers find. Targeting these processes early is likely to offer unexpected therapeutic avenues.

Breast cancers can be classified into subgroups that hint at the aggressiveness of the cancer and the likelihood that the ...

The selective oral CDK4/6 inhibitor lerociclib (GB491) combined with fulvestrant (Faslodex) provided superior progression-free survival (PFS) and tolerability in patients with hormone receptor ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

Giving patients with a common form of breast cancer an immunotherapy drug before surgery appears to boost outcomes, a n ...

For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...